Frede Donskov

29.1k total citations · 3 hit papers
233 papers, 8.4k citations indexed

About

Frede Donskov is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Frede Donskov has authored 233 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 196 papers in Pulmonary and Respiratory Medicine, 102 papers in Cancer Research and 98 papers in Oncology. Recurrent topics in Frede Donskov's work include Renal cell carcinoma treatment (190 papers), Cancer Genomics and Diagnostics (91 papers) and Renal and related cancers (83 papers). Frede Donskov is often cited by papers focused on Renal cell carcinoma treatment (190 papers), Cancer Genomics and Diagnostics (91 papers) and Renal and related cancers (83 papers). Frede Donskov collaborates with scholars based in Denmark, United States and Canada. Frede Donskov's co-authors include Hans von der Maase, Toni K. Choueiri, Brian I. Rini, Georg A. Bjarnason, Lori Wood, Daniel Y.C. Heng, Christian Kollmannsberger, Ulka N. Vaishampayan, Sun Young Rha and Niels Marcussen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Frede Donskov

225 papers receiving 8.3k citations

Hit Papers

External validation and comparison with other models of t... 2013 2026 2017 2021 2013 2020 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
    2013 730 citations Daniel Y.C. Heng, Georg A. Bjarnason et al. profile →
  2. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    2020 347 citations Laurence Albigès, Nizar M. Tannir et al. profile →
  3. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
    2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frede Donskov Denmark 45 5.7k 4.2k 3.3k 2.4k 1.5k 233 8.4k
Daniel Y.C. Heng Canada 41 7.6k 1.3× 3.4k 0.8× 5.0k 1.5× 3.3k 1.4× 380 0.3× 137 9.4k
Jens Bedke Germany 36 3.9k 0.7× 3.0k 0.7× 2.7k 0.8× 1.4k 0.6× 763 0.5× 313 7.6k
Frédéric Rolland France 33 6.7k 1.2× 4.3k 1.0× 4.8k 1.4× 3.0k 1.2× 583 0.4× 142 11.6k
Martin H. Voss United States 40 4.0k 0.7× 2.6k 0.6× 3.1k 0.9× 2.0k 0.8× 662 0.4× 219 6.1k
Laura S. Wood United States 29 3.1k 0.5× 2.3k 0.5× 2.2k 0.7× 1.4k 0.6× 836 0.6× 99 4.9k
Gwénaëlle Gravis France 41 6.3k 1.1× 3.4k 0.8× 2.2k 0.7× 2.1k 0.9× 864 0.6× 368 9.2k
Jennifer Bacik United States 30 5.0k 0.9× 2.1k 0.5× 3.8k 1.2× 2.3k 0.9× 279 0.2× 43 7.4k
Saby George United States 30 2.8k 0.5× 3.3k 0.8× 1.4k 0.4× 966 0.4× 692 0.5× 170 5.0k
Gregory M. Lubiniecki United States 25 8.1k 1.4× 12.2k 2.9× 1.4k 0.4× 1.8k 0.7× 2.9k 1.9× 56 14.3k
Andrea Fülöp Hungary 9 5.3k 0.9× 7.9k 1.9× 898 0.3× 1.2k 0.5× 1.8k 1.2× 14 9.2k

Countries citing papers authored by Frede Donskov

Since Specialization
Citations

This map shows the geographic impact of Frede Donskov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frede Donskov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frede Donskov more than expected).

Fields of papers citing papers by Frede Donskov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frede Donskov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frede Donskov. The network helps show where Frede Donskov may publish in the future.

Co-authorship network of co-authors of Frede Donskov

This figure shows the co-authorship network connecting the top 25 collaborators of Frede Donskov. A scholar is included among the top collaborators of Frede Donskov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frede Donskov. Frede Donskov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berg, Tobias, Maj‐Britt Jensen, Maria Rossing, et al.. (2024). Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer. JAMA Network Open. 7(3). e242174–e242174. 4 indexed citations
2.
Azawi, Nessn, Jane Christensen, Niels Viggo Jensen, et al.. (2024). Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients: A Comprehensive Nationwide Outcome Analysis. Cancers. 16(6). 1132–1132. 1 indexed citations
3.
Nissen, Peter H., Frede Donskov, Agnieszka Woźniak, et al.. (2024). Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism. Clinical Genitourinary Cancer. 22(5). 102180–102180. 1 indexed citations
4.
Azawi, Nessn, Jane Christensen, Niels Viggo Jensen, et al.. (2023). Lifestyle and Clinical Factors in a Nationwide Stage III and IV Renal Cell Carcinoma Study. Cancers. 15(18). 4488–4488. 1 indexed citations
5.
6.
Graham, Jeffrey, J. Connor Wells, Shaan Dudani, et al.. (2022). Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer. 171. 124–132. 20 indexed citations
7.
Navani, Vishal, J. Connor Wells, Devon J. Boyne, et al.. (2022). CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer. 21(1). 106.e1–106.e8. 12 indexed citations
8.
Rini, Brian I., Sabina Signoretti, Toni K. Choueiri, et al.. (2022). Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(12). e005445–e005445. 42 indexed citations
9.
Ebbehøj, Andreas, et al.. (2022). Outcome and prognosis after adrenal metastasectomy: nationwide study. BJS Open. 6(2). 10 indexed citations
10.
Donskov, Frede, Cathy Anne Pinto, Julie Fox, et al.. (2022). Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. Acta Oncologica. 61(10). 1268–1277. 3 indexed citations
11.
McDermott, David F., Jae‐Lyun Lee, Marek Ziobro, et al.. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1029–1039. 183 indexed citations breakdown →
12.
Velasco, Guillermo de, Òscar Reig, Francesco Massari, et al.. (2021). Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. British Journal of Urology. 128(2). 254–261. 2 indexed citations
13.
Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations
14.
Wiley, Henry E., Hanna R. Coleman, Eric Jonasch, et al.. (2021). Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease. Investigative Ophthalmology & Visual Science. 62(8). 32–32. 4 indexed citations
15.
Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106. 1 indexed citations
16.
Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations
17.
18.
George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research. 25(4). 1165–1173. 18 indexed citations
19.
Sternberg, Cora N., Frede Donskov, Naomi B. Haas, et al.. (2018). Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clinical Cancer Research. 24(13). 3005–3013. 45 indexed citations
20.
Donskov, Frede, et al.. (2018). Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician. Oncology and Therapy. 6(1). 1–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Y.C. Heng Breakdown of academic impact, for papers by Jens Bedke Breakdown of academic impact, for papers by Frédéric Rolland Breakdown of academic impact, for papers by Martin H. Voss Breakdown of academic impact, for papers by Laura S. Wood Breakdown of academic impact, for papers by Gwénaëlle Gravis Breakdown of academic impact, for papers by Jennifer Bacik Breakdown of academic impact, for papers by Saby George Breakdown of academic impact, for papers by Gregory M. Lubiniecki Breakdown of academic impact, for papers by Andrea Fülöp
Rankless by CCL
2026